文献速递甲状腺疾病

超越恶性风险分层:细针穿刺细胞学报告可预判甲状腺癌分期——近期研究启示

Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent Studies.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文为评论性文章,由两项近期研究(分别来自欧洲和美国)的资深作者邀请其他甲状腺专家及细胞学家共同撰写。两项研究报告,组织学证实的甲状腺癌的临床行为因其术前细针穿刺细胞学(FNAC)结果而异;尤其对于甲状腺乳头状癌(PTC),初始诊断为不确定甲状腺结节(ITN)的甲状腺癌较初始诊断为「可疑恶性」或「恶性」的分化型甲状腺癌(DTC)临床表现更不侵袭。

要点

  • 初始FNAC为ITN的甲状腺癌较「可疑恶性」或「恶性」者淋巴结转移率更低。
  • 初始FNAC为ITN的甲状腺癌较「可疑恶性」或「恶性」者更具侵袭性变异型的比例更低。
  • 初始FNAC为ITN的甲状腺癌较「可疑恶性」或「恶性」者BRAFV600E突变率更低。

核心结论

  • 初始诊断为ITN的甲状腺癌(尤其PTC)较初始诊断为「可疑恶性」或「恶性」的DTC临床表型更趋向惰性。
  • 上述结果在两项研究中一致,作者认为进一步理解这些数据的临床意义具有临床相关性。
  • 所综述数据为开始探讨对初始ITN诊断的甲状腺癌采用侵袭性更低的治疗的影响提供了基础。

研究设计与样本

  • 本文为评论性文章,由两项近期研究(分别来自欧洲和美国)的资深作者邀请未参与前两项研究的其他甲状腺专家和细胞学家共同参与撰写。
  • 两项研究在 study design、纳入标准及所用细胞学分类系统(意大利系统与Bethesda系统)上存在差异。

主要发现

  • 两项研究均报告,组织学证实的甲状腺癌的临床行为因其术前FNAC结果而异。
  • 初始诊断为ITN的甲状腺癌较初始诊断为「可疑恶性」或「恶性」的DTC淋巴结转移率更低。
  • 初始诊断为ITN的甲状腺癌较初始诊断为「可疑恶性」或「恶性」的DTC更具侵袭性变异型的比例更低。
  • 初始诊断为ITN的甲状腺癌较初始诊断为「可疑恶性」或「恶性」的DTC BRAFV600E突变率更低。
  • 尽管两项研究的 study design、纳入标准及细胞学分类系统不同,总体结果具有可比性。

临床怎么用

  • 作者认为,进一步理解这些数据的临床意义具有临床相关性,并从内分泌科医生和细胞学家的角度进行了讨论。
  • 所综述数据为开始探讨对初始ITN诊断的甲状腺癌采用侵袭性更低的治疗的影响提供了基础。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fine-needle-aspiration-cytology (FNAC) is safe and cost-effective procedure for evaluating thyroid nodules. The non-negligible rate of indeterminate thyroid nodule (ITN) cytology warrants diagnostic surgery for histological assessment, in some cases. Two recent studies (from Europe and the United States) reported that the clinical behavior of a histologically proven thyroid cancer (TC) varies according to its presurgical FNAC results. Despite differences in study design, inclusion criteria, and the use of different cytology classification systems (Italian and Bethesda), the overall results were comparable. In order to further discuss these results and to provide additional perspective on the topic, the senior authors of the 2 studies invited other thyroid experts and cytologists not involved in the previous studies to participate in the present commentary. The strong, consistent clinical message that emerges, especially regarding PTC, is that TC with an initial diagnosis of ITN has a less aggressive clinical presentation, lower rates of (1) lymph node metastasis; (2) more aggressive variants; and (3) BRAFV600E mutations compared with differentiated thyroid cancer (DTC) with an initial diagnosis of "suspicious for malignancy" or "malignant." These results were consistent in both studies and strongly point toward a more indolent clinical phenotype of DTC with a preoperative diagnosis of ITN as opposed to suspicious for malignancy or malignant. Further understanding the clinical implications of these data appears of clinical relevance and will be discussed from both the endocrinologist and the cytologist point of view. The here overviewed data provide the foundation for beginning to examine the impact of less aggressive therapies for TC with an initial ITN diagnosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rotondi M, Endo M, Teliti M, et al. Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent Studies. J Clin Endocrinol Metab. 2025. PMID: 39353065. doi:10.1210/clinem/dgae675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。